A Phase 4 interventional study of RemifentanilMNTX and PlaceboMNTX in Pharyngeal Dysfunction and Pharyngeal Swallowing, sponsored by Region Örebro County. Status unknown at 1 site in Sweden. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-12.
Sponsored by Region Örebro County · Phase 4, Interventional, and Basic science
The purpose of the study is to evaluate the impact of different bolus volumes and viscosity on remifentanil-induced swallowing dysfunction in healthy volunteers.Hence, whether swallowing tasks can be done safer during sedation by altering bolus volumes and viscosities will be revealed. Furthermore, the study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. If methylnaltrexone reverses the remifentanil-induced effects on swallowing, this would suggest a dominant peripherally mediated mechanism.
Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.
Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.
The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.
20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.
Exclusion Criteria:
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Drug: RemifentanilMNTX
Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Drug: PlaceboMNTX
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Also known as: Methylnaltrexone, Remifentanil, Relistor, Ultiva
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Also known as: Sodium Chloride 0.9%, Methylnaltrexone, Relistor
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
Time frame: Up to 60 minutes
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
Time frame: Up to 60 minutes
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Time frame: Up to 60 minutes
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
Time frame: Up to 60 minutes
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
Time frame: Up to 60 minutes
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
Time frame: Up to 60 minutes
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Time frame: Up to 60 minutes
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
Time frame: Up to 60 minutes
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Örebro County